Literature DB >> 21251820

Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging.

Yunpeng Ye1, Lei Zhu, Ying Ma, Gang Niu, Xiaoyuan Chen.   

Abstract

Recently, a disulfide-based cyclic RGD peptide called iRGD, that is, c(CRGDKGPDC), has been reported to interact with both integrin and neuropilin-1 receptors for cellular and deep tissue penetration to improve the imaging sensitivity and therapeutic efficacy. In this study, two new near-infrared fluorescent iRGD conjugates, that is, Ac-Cys(IRDye®800CW)-iRGD (1), and its dual labeling analog DOTA-Cys(IRDye®800CW)-iRGD (2) were synthesized via the specific mercapto-maleimide reaction for tumor imaging. Both 1 and 2 showed significant tumor localization in optical imaging of MDA-MB-435 tumor-bearing mice. The potential of such iRGD compounds in tumor-targeted imaging and drug delivery deserves further exploration. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21251820      PMCID： PMC3038550          DOI： 10.1016/j.bmcl.2010.12.112

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  37 in total

Review 1.  Integrins: signaling, disease, and therapy.

Authors:  Stephan Huveneers; Hoa Truong; H J Danen
Journal:  Int J Radiat Biol       Date:  2007 Nov-Dec       Impact factor: 2.694

2.  Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots.

Authors:  Willem J M Mulder; Karolien Castermans; Judy R van Beijnum; Mirjam G A Oude Egbrink; Patrick T K Chin; Zahi A Fayad; Clemens W G M Löwik; Eric L Kaijzel; Ivo Que; Gert Storm; Gustav J Strijkers; Arjan W Griffioen; Klaas Nicolay
Journal:  Angiogenesis       Date:  2008-12-09       Impact factor: 9.596

3.  Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting.

Authors:  Leonardo Manzoni; Laura Belvisi; Daniela Arosio; Monica Civera; Michael Pilkington-Miksa; Donatella Potenza; Andrea Caprini; Elena M V Araldi; Eugenia Monferini; Monica Mancino; Francesca Podestà; Carlo Scolastico
Journal:  ChemMedChem       Date:  2009-04       Impact factor: 3.466

4.  Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis [corrected].

Authors:  Felix Rosenow; Rainer Ossig; Dorit Thormeyer; Peter Gasmann; Kerstin Schlüter; Georg Brunner; Jörg Haier; Johannes A Eble
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

5.  Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide.

Authors:  W Barry Edwards; Walter J Akers; Yunpeng Ye; Philip P Cheney; Sharon Bloch; Baogang Xu; Richard Laforest; Samuel Achilefu
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

6.  (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.

Authors:  Lihui Wei; Yunpeng Ye; Thaddeus J Wadas; Jason S Lewis; Michael J Welch; Samuel Achilefu; Carolyn J Anderson
Journal:  Nucl Med Biol       Date:  2009-04       Impact factor: 2.408

Review 7.  New targeted probes for radioimaging of angiogenesis.

Authors:  T H Stollman; T J M Ruers; W J G Oyen; O C Boerman
Journal:  Methods       Date:  2009-03-24       Impact factor: 3.608

8.  Ligands for mapping alphavbeta3-integrin expression in vivo.

Authors:  Margret Schottelius; Burkhardt Laufer; Horst Kessler; Hans-Jürgen Wester
Journal:  Acc Chem Res       Date:  2009-07-21       Impact factor: 22.384

9.  Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

Authors:  Andrew R Reynolds; Ian R Hart; Alan R Watson; Jonathan C Welti; Rita G Silva; Stephen D Robinson; Georges Da Violante; Morgane Gourlaouen; Mishal Salih; Matt C Jones; Dylan T Jones; Garry Saunders; Vassiliki Kostourou; Françoise Perron-Sierra; Jim C Norman; Gordon C Tucker; Kairbaan M Hodivala-Dilke
Journal:  Nat Med       Date:  2009-03-22       Impact factor: 53.440

10.  Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature.

Authors:  Oliver Schnell; Bjarne Krebs; Erika Wagner; Alexander Romagna; Ambros J Beer; Stefan J Grau; Niklas Thon; Claudia Goetz; Hans A Kretzschmar; Jörg-Christian Tonn; Roland H Goldbrunner
Journal:  Brain Pathol       Date:  2008-04-02       Impact factor: 6.508
View more
  14 in total

1.  Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.

Authors:  Zheng-Hong Peng; Jindřich Kopeček
Journal:  Bioorg Med Chem Lett       Date:  2014-03-12       Impact factor: 2.823

2.  Near-infrared fluorescent divalent RGD ligand for integrin αvβ₃-targeted optical imaging.

Authors:  Yunpeng Ye; Walter Akers; Baogang Xu; Sharon Bloch; Charles Odonkor; Samuel Achilefu
Journal:  Bioorg Med Chem Lett       Date:  2012-07-20       Impact factor: 2.823

3.  Evaluation of 68Ga-labeled iNGR peptide with tumor-penetrating motif for microPET imaging of CD13-positive tumor xenografts.

Authors:  Mingxuan Zhao; Weidong Yang; Mingru Zhang; Guoquan Li; Shengjun Wang; Zhe Wang; Xiaowei Ma; Fei Kang; Jing Wang
Journal:  Tumour Biol       Date:  2016-05-24

4.  A high-affinity near-infrared fluorescent probe to target bombesin receptors.

Authors:  Ajay Shrivastava; Haiming Ding; Shankaran Kothandaraman; Shu-Huei Wang; Li Gong; Michelle Williams; Keisha Milum; Song Zhang; Michael F Tweedle
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

5.  An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy.

Authors:  Shichao Ai; Shuang Zhen; Zhijian Liu; Feng Sun; Xingchen He; Feng Chu; Wenxian Guan; Jianquan Wang
Journal:  RSC Adv       Date:  2018-08-24       Impact factor: 4.036

6.  Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.

Authors:  Hong-Jun Cho; Sung-Jin Lee; Sung-Jun Park; Chang H Paik; Sang-Myung Lee; Sehoon Kim; Yoon-Sik Lee
Journal:  J Control Release       Date:  2016-06-24       Impact factor: 9.776

7.  Cellular density effect on RGD ligand internalization in glioblastoma for MRI application.

Authors:  Damien Moncelet; Véronique Bouchaud; Philippe Mellet; Emeline Ribot; Sylvain Miraux; Jean-Michel Franconi; Pierre Voisin
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

8.  Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment.

Authors:  Gejing De; Jae-Kyun Ko; Tao Tan; Hua Zhu; Haichang Li; Jianjie Ma
Journal:  Oncotarget       Date:  2014-09-15

9.  Increasing Tumor Accessibility with Conjugatable Disulfide-Bridged Tumor-Penetrating Peptides for Cancer Diagnosis and Treatment.

Authors:  Venkata Ramana Kotamraju; Shweta Sharma; Poornima Kolhar; Lilach Agemy; James Pavlovich; Erkki Ruoslahti
Journal:  Breast Cancer (Auckl)       Date:  2016-06-27

10.  Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.

Authors:  Cuihua Hu; Xiaolong Chen; Yibing Huang; Yuxin Chen
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.